Pivotal Data for the Investigational Treatment PSD502 for Primary Premature Ejaculation in the United States to be …

Published June 1, 2010

Pivotal Data for the Investigational Treatment PSD502 for Primary Premature Ejaculation in the United States to be …
Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray, being developed for the treatment of primary premature ejaculation . Â These data were presented at the 2010 American Urological Association Annual Meeting in San Francisco.

Read more on PR Newswire via Yahoo! Finance